Residency · Residency · Internal Medicine

Anticoagulation Reversal and Periprocedural Management

Overview

Management of bleeding on anticoagulation and periprocedural anticoagulation decisions are essential hospitalist skills. Specific reversal agents exist for warfarin, dabigatran, and factor Xa inhibitors. The BRIDGE trial fundamentally changed practice around perioperative bridging for atrial fibrillation. All decision-making in this space balances bleeding risk against thromboembolic risk.

Reversal Agents

Warfarin Reversal

Vitamin K (phytonadione) can be given IV at 10 mg via slow infusion with onset in 6 to 12 hours and full effect at 24 hours, or orally at 2.5 to 5 mg with onset in 24 to 48 hours for non-urgent reversal. Anaphylactoid reactions with IV administration are rare but reported, so slow infusion is used.

Four-factor prothrombin complex concentrate (PCC, brand name KCentra) contains factors II, VII, IX, and X along with proteins C and S. It is dosed at 25 to 50 units/kg based on INR with an onset of 15 to 30 minutes, making it preferred for life-threatening bleeding or urgent surgery. Its advantages over FFP include faster action, smaller volume without fluid overload risk, and no need for blood type matching.

Fresh frozen plasma is dosed at 10 to 15 mL/kg with onset in 30 to 60 minutes. It requires thawing time, ABO compatibility, and large volume administration. It is inferior to PCC for urgent reversal but remains useful when PCC is unavailable. Activated charcoal is appropriate if warfarin was ingested within 2 hours.

Dabigatran Reversal

Idarucizumab (Praxbind) is a humanized monoclonal antibody fragment against dabigatran, given as 5 g IV in two 2.5 g boluses. It achieves complete reversal within 15 minutes, and the RE-VERSE AD trial demonstrated hemostasis in 68% of patients with uncontrolled bleeding. Activated charcoal is effective if ingested within 2 hours. Hemodialysis is an option since dabigatran is 35% dialyzable, a property unique among DOACs. Four-factor PCC may provide partial hemostatic benefit if idarucizumab is unavailable.

Factor Xa Inhibitor Reversal (Rivaroxaban, Apixaban, Edoxaban)

Andexanet alfa (Andexxa) is a recombinant modified factor Xa decoy that binds and sequesters factor Xa inhibitors. It is given as a low-dose or high-dose bolus plus infusion depending on the timing and specific agent involved. The ANNEXA-4 trial showed effective hemostasis in approximately 82%. However, it is extremely expensive (over $25,000-50,000 per dose), associated with thrombotic events in 10-18% of cases, and requires a 2-hour infusion due to its short half-life.

Four-factor PCC at 50 units/kg is increasingly favored over andexanet alfa due to cost, availability, and comparable observational outcomes. Multiple observational studies suggest similar hemostatic efficacy. While it does not directly reverse the drug, it provides substrate for thrombin generation. Activated charcoal is again appropriate if ingested within 2 hours.

<image>Anticoagulation reversal agent summary showing specific reversal agents for warfarin (vitamin K, PCC, FFP), dabigatran (idarucizumab), and factor Xa inhibitors (andexanet alfa, PCC) with onset times and key considerations</image>

Heparin Reversal

Unfractionated heparin is reversed with protamine sulfate at 1 mg per 100 units UFH given in the last 2 to 3 hours, with a maximum of 50 mg. LMWH is partially reversed by protamine (approximately 60%) at 1 mg per 1 mg enoxaparin within 8 hours. Fondaparinux has no specific reversal agent; recombinant factor VIIa (off-label) or PCC may be considered.

Management of Bleeding on Anticoagulation

General Approach

The approach begins with assessing severity and hemodynamic stability, applying direct pressure to compressible bleeding sites, stopping anticoagulation, administering the specific reversal agent based on the anticoagulant, transfusing blood products as needed, obtaining urgent imaging if intracranial hemorrhage is suspected, and pursuing source control through endoscopy, interventional radiology, or surgery.

Intracranial Hemorrhage

This is the most feared complication of anticoagulation and requires immediate reversal regardless of the indication for anticoagulation. For warfarin-related ICH, 4-factor PCC plus IV vitamin K 10 mg with a target INR below 1.4 within 1 hour is the standard. For DOAC-related ICH, idarucizumab is used for dabigatran, and PCC or andexanet alfa for factor Xa inhibitors. Systolic blood pressure should be targeted below 140 mmHg based on the INTERACT2 and ATACH-2 trials. Neurosurgery consultation for surgical evacuation is obtained when indicated.

GI Bleeding on Anticoagulation

The GI tract is the most common site of major bleeding on anticoagulation. Anticoagulation is withheld with reversal if hemodynamically significant. A restrictive transfusion strategy targeting hemoglobin below 7 is used unless there is active massive hemorrhage or ACS. Endoscopy within 24 hours allows risk stratification and intervention. Timing of anticoagulation resumption is individualized, generally 7 to 14 days after hemostasis is achieved if thromboembolic risk is high.

<image>Management algorithm for major bleeding on anticoagulation showing parallel pathways for hemodynamic stabilization, specific reversal, and source control with timing of anticoagulation resumption</image>

Periprocedural Anticoagulation Management

DOAC Perioperative Management

DOACs follow a simple hold/restart protocol with no bridging needed. For minimal bleeding risk procedures (dental extraction, cataract surgery, pacemaker implant), the DOAC may be continued or one dose held. For low bleeding risk procedures, hold 24 to 48 hours before (1-2 half-lives). For high bleeding risk procedures (major surgery), hold 48 to 72 hours before (2-3 half-lives). Dabigatran requires longer holds in CKD (72-96 hours for high-risk procedures when CrCl is 30-50). Resumption occurs 24 to 72 hours post-procedure based on hemostasis and procedure risk.

Warfarin Perioperative Management

Warfarin is stopped 5 days before the procedure with a target INR below 1.5. INR is checked the day before or morning of the procedure. Warfarin is resumed the evening of or day after the procedure, taking 3 to 5 days to reach therapeutic levels.

Bridging Decisions (Warfarin Patients)

The BRIDGE trial showed that no-bridging was non-inferior to bridging with LMWH for AF patients undergoing procedures, and bridging increased major bleeding. Bridging with therapeutic LMWH should still be considered for mechanical mitral valves, recent VTE (less than 3 months), or very high thromboembolic risk. Bridging should not be used for AF without other high-risk features (the majority of patients) or VTE more than 3 months ago. When bridging is indicated, it starts 3 days before the procedure, stops 24 hours before, and resumes 48 to 72 hours after.

Urgent/Emergent Surgery

The approach involves assessing the last dose of anticoagulant and its half-life, checking anti-Xa levels for factor Xa inhibitors, thrombin time or dilute thrombin time for dabigatran, and INR for warfarin. A reversal agent is administered if surgery cannot be delayed, though a delay of 12 to 24 hours should be considered when possible to allow drug clearance.

Specific Scenarios

Mechanical Heart Valves

These always require warfarin since DOACs are contraindicated (the RE-ALIGN trial was stopped early due to increased thromboembolic events with dabigatran). Target INR is 2.0-3.0 for aortic valves and 2.5-3.5 for mitral valves. All mechanical valves require perioperative bridging with LMWH or UFH.

Acute Coronary Syndrome + Anticoagulation

Triple therapy (anticoagulant plus dual antiplatelet) increases bleeding risk substantially. The duration of triple therapy should be minimized to 1 week to 1 month, then transitioned to dual therapy (anticoagulant plus single antiplatelet, usually clopidogrel). Reduced-dose rivaroxaban 15 mg daily or apixaban 5 mg twice daily is used with antiplatelet therapy.

Post-Procedure VTE Risk

Most procedures carry higher bleeding than thromboembolic risk in the first 48 hours. Anticoagulation should be resumed as soon as hemostasis is assured, with mechanical prophylaxis (SCDs) used while anticoagulation is held.

<image>Periprocedural DOAC management timeline showing hold periods before low and high bleeding risk procedures based on half-lives and renal function, with post-procedure resumption timing</image>

Clinical Pearls

Four-factor PCC is increasingly preferred over andexanet alfa for factor Xa inhibitor reversal because observational data suggest comparable efficacy at a fraction of the cost. IV vitamin K must always be given alongside PCC for warfarin reversal since PCC provides immediate factor replacement but wears off in 12 to 24 hours, while vitamin K ensures sustained reversal. Dabigatran is the only DOAC removable by hemodialysis, which should be considered in overdose or when idarucizumab is unavailable. After intracranial hemorrhage on anticoagulation, the decision to restart is complex and generally considered at 4 to 8 weeks with multidisciplinary discussion involving neurology and cardiology. The PAUSE trial validated a simple perioperative DOAC management strategy (hold 1-2 days for low-risk, 2-3 days for high-risk procedures) without measuring drug levels, demonstrating it is both practical and safe. Warfarin should never be started in acute HIT because protein C depletion can cause venous limb gangrene; wait until platelets recover above 150,000.

References

• Douketis JD, et al. Perioperative Bridging Anticoagulation in AF (BRIDGE). N Engl J Med. 2015;373:823-833.
• Pollack CV, et al. Idarucizumab for Dabigatran Reversal (RE-VERSE AD). N Engl J Med. 2017;377:431-441.
• Connolly SJ, et al. Andexanet Alfa for Factor Xa Inhibitor Reversal (ANNEXA-4). N Engl J Med. 2019;380:1326-1335.
• Douketis JD, et al. Perioperative Management of DOACs (PAUSE). N Engl J Med. 2019;381:1524-1534.
• Frontera JA, et al. Guideline for Reversal of Antithrombotics in ICH. Neurocrit Care. 2016;24:6-46.

Read this lecture as Markdown